Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 6.2% – Still a Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Free Report)’s share price was up 6.2% during mid-day trading on Tuesday . The company traded as high as $121.98 and last traded at $121.74. Approximately 264,264 shares traded hands during trading, a decline of 78% from the average daily volume of 1,227,246 shares. The stock had previously closed at $114.65.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SRPT shares. Guggenheim increased their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $205.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, November 7th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Robert W. Baird lowered their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $176.73.

Read Our Latest Stock Report on Sarepta Therapeutics

Sarepta Therapeutics Trading Up 9.6 %

The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a 50 day moving average of $121.80 and a 200 day moving average of $131.40. The firm has a market cap of $12.01 billion, a price-to-earnings ratio of 98.18 and a beta of 0.81.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 14.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 7.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently bought and sold shares of SRPT. Innealta Capital LLC bought a new position in Sarepta Therapeutics in the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. bought a new stake in Sarepta Therapeutics in the first quarter valued at approximately $32,000. Nkcfo LLC acquired a new stake in Sarepta Therapeutics during the 2nd quarter worth $43,000. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares during the period. Finally, Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the period. 86.68% of the stock is currently owned by institutional investors.

About Sarepta Therapeutics

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Recommended Stories

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.